Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Pepscan Hits First Genmab Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Pepscan Hits First Genmab Milestone

Pepscan Therapeutics has earned a milestone payment from Genmab from an ongoing research collaboration aimed at identifying human antibodies against intractable targets.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Pepscan Therapeutics has earned a milestone payment from Genmab from an ongoing research collaboration aimed at identifying human antibodies against intractable targets. Pepscan is responsible for using its CLIPS technology to generate immunogens that mimic the protein targets to induce human antibodies against these intractable targets.

Pepscan is eligible to receive additional payments based on certain development and regulatory milestones and is eligible to receive royalties on potential sales of any therapeutics developed as a result of the collaboration.

“The achievement of this milestone further validates Pepscan’s CLIPS platform,” said Rob Meloen, chief scientific officer of Pepscan Therapeutics. “We are pleased to see the significant progress that has been made in the collaboration with Genmab.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters